Sibeprenlimab: IgA Nephropathy Trial Results
- A novel antibody, sibeprenlimab, is showing promise in treating immunoglobulin A (IgA) nephropathy.
- The study, presented at the 62nd European Renal Association Congress, revealed that sibeprenlimab decreased the urine protein-to-creatinine ratio (uPCR) by more than 50%.
- IgA nephropathy, frequently enough diagnosed between ages 20 and 40, carries a high risk of end-stage kidney disease (ESKD).
Sibeprenlimab is revolutionizing IgA nephropathy treatment, and News Directory 3 has the details. The VISIONARY trial’s interim analysis reveals that this novel antibody dramatically reduced proteinuria, a key indicator, in patients with this condition. Specifically, results show a compelling 50.2% reduction in urine protein-to-creatinine ratio (uPCR), outperforming existing treatments. Moreover, the study highlighted no major safety concerns, offering added promise. IgA nephropathy patients, often diagnosed in early adulthood, face significant risks; therefore, the emergence of new treatments is crucial. Explore the latest advancements in kidney disease research and discover what’s next in this groundbreaking trial.
novel Antibody Shows Promise in IgA Nephropathy Treatment
Updated June 06, 2025
A novel antibody, sibeprenlimab, is showing promise in treating immunoglobulin A (IgA) nephropathy. Interim results from the VISIONARY trial indicate the selective immune antibody significantly reduced proteinuria in patients.
The study, presented at the 62nd European Renal Association Congress, revealed that sibeprenlimab decreased the urine protein-to-creatinine ratio (uPCR) by more than 50%. Vlado Perkovic, MD, PhD, from the University of New South Wales, highlighted the importance of these findings, notably the lack of significant safety concerns.
IgA nephropathy, frequently enough diagnosed between ages 20 and 40, carries a high risk of end-stage kidney disease (ESKD). Up to half of all patients progress to ESKD within 20 years. Perkovic suggested the condition’s impact may be underestimated, adding that new treatments are emerging.
The VISIONARY trial, involving 240 sites across 31 countries, randomized patients with biopsy-confirmed IgA nephropathy to receive either sibeprenlimab or a placebo over 100 weeks, followed by a 12-week observation period. All participants had a uPCR of ≥ 0.75 g/g and an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2.
The interim analysis focused on 320 patients, assessing the primary endpoint of 24-hour uPCR at nine months compared to baseline. Results showed sibeprenlimab led to a 50.2% reduction in uPCR,a significant betterment compared to the placebo group (P < .0001). The benefit was observed as early as four weeks into treatment.
“Safety’s been a key consideration with these drugs,” said Perkovic, emphasizing the careful monitoring of potential infection risks associated with immune-modulating therapies.
Ronald T. Gansevoort, MD, PhD, a nephrologist at the University Medical Center Groningen, Netherlands, described the results as “very promising,” noting that the proteinuria lowering seen in VISIONARY appears to be the best observed so far with this class of agents. He awaits the kidney function data with great interest.
Regarding safety, treatment-related adverse events were slightly lower in the sibeprenlimab group (32.9%) compared to the placebo group (31.0%).Serious adverse events were also less frequent with the experimental drug.While infection rates were numerically higher in the sibeprenlimab group, Perkovic stated there was “no suggestion of an increased risk of infection.”
what’s next
Further data from the ongoing VISIONARY trial will be crucial to confirm these encouraging interim findings.If the final results support both the efficacy and safety outcomes, sibeprenlimab could represent a significant advancement in treating the underlying causes of IgA nephropathy.